P

    PDS Biotechnology Corp (PDSB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.21
    +0.00 (+1.47%)

    Market Cap: $11.80M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(23/38)
    Avg Surprise
    -22.86%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.11 - $-0.11
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.12-6.1%
    60d ago$-0.12-6.1%
    30d ago$-0.12-6.1%
    7d ago$-0.12-9.1%
    Current$-0.11
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.11---
    Jun 26
    		$-0.18$-0.13-38.46%Miss+14.3%
    Mar 26
    		$-0.13$-0.14+7.14%Beat+38.1%
    Dec 25
    		$-0.14$-0.18+20.77%Beat+33.3%
    Sep 25
    		$-0.19$-0.20+5.00%Beat+34.5%
    Jun 25
    		$-0.21$-0.23+8.70%Beat+8.7%
    Mar 25
    		$-0.21$-0.25+16.00%Beat+30.0%
    Dec 24
    		$-0.21$-0.28+23.64%Beat+40.0%
    Sep 24
    		$-0.29$-0.28-3.57%Miss+17.1%
    Jun 24
    		$-0.23$-0.33+30.30%Beat+37.8%
    Mar 24
    		$-0.30$-0.37+18.92%Beat+6.3%
    Dec 23
    		$-0.35$-0.42+16.67%Beat+47.8%
    Sep 23
    		$-0.35$-0.47+25.53%Beat-34.6%
    Jun 23
    		$-0.37$-0.34-8.82%Miss-85.0%
    Mar 23
    		$-0.32$-0.30-6.67%Miss+0.0%
    Dec 22
    		$-0.67$-0.29-131.03%Miss-204.5%
    Sep 22
    		$-0.26$-0.28+7.14%Beat-13.0%
    Jun 22
    		$-0.20$-0.28+28.57%Beat+9.1%
    Mar 22
    		$-0.32$-0.22-45.45%Miss-128.6%
    Dec 21
    		$-0.22$-0.24+8.33%Beat-22.2%
    Sep 21
    		$-0.23$-0.20-15.00%Miss+0.0%
    Jun 21
    		$-0.22$-0.16-37.50%Miss-15.8%
    Mar 21
    		$-0.14$-0.17+17.65%Beat+64.1%
    Dec 20
    		$-0.18$-0.19+5.26%Beat+78.6%
    Sep 20
    		$-0.23$-0.14-64.29%Miss+75.0%
    Jun 20
    		$-0.19$-0.23+17.39%Beat+74.7%
    Mar 20
    		$-0.39$-0.15-160.00%Miss-126.5%
    Dec 19
    		$-0.84$-0.92+8.70%Beat-740.0%
    Sep 19
    		$-0.92$-0.82-12.20%Miss+59.8%
    Jun 19
    		$-0.75N/AN/ABeat+90.9%
    Mar 19
    		$1.47N/AN/ABeat+111.0%
    Dec 18
    		$-0.10N/A+96.15%Beat+98.9%
    Sep 18
    		$-2.29$-0.27-748.15%Miss+69.1%
    Jun 18
    		$-8.20$-10.52+22.05%Beat+6.8%
    Mar 18
    		$-13.40$-10.52-27.38%Miss-59.5%
    Dec 17
    		$-9.00$-8.62-4.41%Miss-36.4%
    Sep 17
    		$-7.40$-9.55+22.51%Beat+0.0%
    Jun 17
    		$-8.80$-8.74-0.69%Miss-
    Mar 17
    		$-8.40$-8.45+0.59%Beat-
    Dec 16
    		$-6.60$-8.31+20.58%Beat-
    Sep 16
    		$-7.40$-7.97+7.15%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.33EV/EBITDA-2.58x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-544.00%ROIC-2960.28%
    Financial Health
    Debt/Equity-1.21xInterest Coverage-4.18x
    Current Ratio0.57xQuick Ratio0.57x
    Trading Statistics
    Beta1.55Avg Volume2.91M
    52-Week High$1.5552-Week Low$0.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.21
    SMA 20$0.35
    SMA 50$0.61
    SMA 200$0.82
    EMA 10$0.24
    EMA 20$0.34
    EMA 50$0.55
    EMA 200$0.83

    MACD

    Line: -0.13Signal: -0.14Hist: 0.01

    ADX

    ADX: 44.4+DI: 14.2-DI: 38.3

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down68.0
    PSAR$0.35

    Bollinger Bands

    Upper Band$0.81
    Lower Band$-0.11
    %B Position26298%(Upper)
    Band Width0.35

    RSI (14-Day)

    Oversold
    20.6

    Momentum Oscillators

    Stoch %K10.5
    Stoch %D6.2
    Williams %R-75.5
    ROC (10d)-2.9%
    Momentum-0.01
    CCI (20d)-49.1
    MFI (14d)26.6

    Volatility Measures

    ATR (14d)$0.05(21.2%)
    StdDev (20d)0.23
    Hist Vol233.8%(High)

    Volume Flow

    VWAP$0.22
    OBV-39.4M
    AD Line-80.6M
    CMF (20d)-0.557

    Volume Metrics

    Avg Vol (20d)3.0M
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.25

    Pivot Points

    R3$0.24
    R2$0.23
    R1$0.22
    Pivot Point$0.21
    S1$0.20
    S2$0.20
    S3$0.19

    Advanced Oscillators

    TSI-59.74
    Ultimate Osc35.3
    KST-676.79

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$59,066$0$0$0$0$0
    Cost of Revenue$0$0$15,131$0$0$0$15,127$0$0$0$14,405$0
    Gross Profit$0$0$-15,131$0$0$0$-15,127$0$0$0$-14,405$0
    Operating Expenses$6.50M$6.52M$6.67M$8.14M$7.62M$9.11M$7.36M$10.18M$8.68M$10.10M$10.41M$10.52M
    R&D$3.27M$3.46M$4.41M$4.58M$4.21M$5.83M$4.53M$6.80M$4.53M$6.70M$7.47M$6.45M
    SG&A$3.23M$3.06M$2.27M$3.56M$3.41M$3.27M$2.83M$3.37M$4.16M$3.39M$2.94M$4.07M
    Operating Income$-6,496,734$-6,521,087$-6,674,708$-8,140,142$-7,623,351$-9,105,758$-7,360,570$-10,178,694$-8,684,304$-10,097,627$-10,406,961$-10,519,686
    Interest Income$125,405$186,814$224,659$281,109$333,624$377,849$503,942$666,770$675,209$668,895$683,540$739,404
    Interest Expense$3.38M$1.01M$1.11M$1.15M$2.14M$930,878$1.10M$1.21M$1.19M$1.17M$1.17M$1.07M
    Income Before Tax$-9,750,575$-7,349,056$-7,562,919$-9,009,411$-9,434,208$-9,658,787$-7,952,352$-10,726,658$-9,197,066$-10,603,477$-10,898,214$-10,849,169
    Income Tax Expense$0$0$0$0$0$-1,169,820$0$0$-869,169$0$0$0
    Net Income$-9,750,575$-7,349,056$-7,562,919$-9,009,411$-9,434,208$-8,488,967$-7,952,352$-10,726,658$-8,327,897$-10,603,477$-10,898,216$-10,849,169
    EBITDA$-6,216,056$-6,057,121$-6,185,169$-8,412,852$-6,494,194$-8,818,051$-7,047,673$-9,858,438$-8,375,732$-9,822,656$-10,102,173$-10,377,183
    EBIT$-6,496,734$-6,521,087$-6,674,708$-8,140,142$-7,623,351$-9,105,758$-7,360,570$-10,178,694$-8,684,304$-10,097,627$-10,406,961$-10,519,686
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PDSB

    News

    PDS Biotechnology (PDSB) to shed 36% of staff and part ways with COO

    PDS Biotechnology (PDSB) announced a significant workforce reduction of approximately 36% to align operating expenses with strategic priorities, focusing on its PDS0301 program. This restructuring, approved on August 6, 2026, is expected to result in a one-time charge of about $842,000 for employee separation benefits in Q3 2026. Additionally, the company terminated its Chief Operating Officer, Stephan Toutain, without cause, entitling him to severance benefits.

    Stock Titan•8/25/26•
    Bearish

    Form 8K PDS Biotechnology Corp For: 19 August By Investing.com

    Investing.com reports on PDS Biotechnology Corp's Form 8K filing for August 19th. The article primarily consists of this brief announcement along with various financial market data, news headlines, and stock performance listings from Investing.com.

    Investing.com Nigeria•8/19/26•
    Neutral

    PDS Biotechnology announces CFO resignation and interim appointments

    PDS Biotechnology Corporation announced the resignation of CFO Lars Boesgaard, effective September 12, 2026. Janetta Trochimiuk has been appointed interim Principal Accounting Officer and CEO Frank Bedu-Addo will serve as interim Principal Financial Officer. Separately, shareholders approved an amendment to increase the authorized common stock from 150 million to 300 million shares.

    Investing.com•8/19/26•
    Neutral

    PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

    PDS Biotechnology Corp (PDSB) announced that CFO Lars Boesgaard resigned, effective September 12, 2026, to pursue other opportunities, with no disagreements cited. Following his departure, the board appointed Janetta Trochimiuk, the company's Controller, as interim Principal Accounting Officer and CEO Frank Bedu-Addo, Ph.D., as interim Principal Financial Officer. Ms. Trochimiuk, 63, brings over 25 years of finance experience and will maintain her Controller role and salary, remaining eligible for equity awards.

    Stock Titan•8/19/26•
    Neutral

    PDS Biotechnology shareholders approve charter amendment and director elections

    PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP as their independent registered public accounting firm. A non-binding advisory vote on executive compensation was also approved, and InvestingPro analysis suggests the company may be undervalued.

    Investing.com•8/14/26•
    Somewhat-Bullish

    Frequently Asked Questions About PDSB

    Does PDSB pay dividends?
    PDS Biotechnology Corp (PDSB) does not currently pay a regular dividend.
    What is PDSB's market cap?
    PDS Biotechnology Corp (PDSB) has a market capitalization of $11.80M with a current stock price of $0.21.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In